Taylor Wessing advises UCB on an expanded product license agreement with Jazz Pharmaceuticals

13-Jan-2007  |  Corporate, Life Sciences & Healthcare

CLIENT

UCB

VALUE

Transaction ongoing

TRANSACTION

Licensing deal

DESCRIPTION

Advising UCB on an expanded product license agreement for Xyrem (sodium oxybate) with Jazz Pharmaceuticals, Inc. Under the agreement, UCB obtains the right to commercialise Xyrem for the treatment of fibromyalgia syndrome